PVALB and schizophrenia: In animal models of schizophrenia, NAC has already been successfully used to prevent changes in sensory gating functions (Lutgen et al., 2013; Cabungcal et al., 2014), as well as changes in parvalbumin-expressing interneurons, which are believed to be at the hub of many network changes in the brains of schizophrenic patients (Lewis et al., 2012).